Pathogenesis and treatment of IgA NephropathyVinci Congress Center - 26, Boulevard Heurteloup
37000 Tours France
Pathogenesis and treatment of IgA Nephropathy
Vinci Congress Center , Tours , France
September 16, 2016
Vinci Congress Center - 26, Boulevard Heurteloup , Tours , France
ERA-EDTA Immunonephrology Working Group
Local Coordinator/Contact Person for information
Dr. Renato Monteiro, E-mail: email@example.com
Center for Research on Inflammation (CRI) - INSERM (Institut national de la
santé et de la recherche médicale) Unit 1149, Phone: +33 184.108.40.206.55
IgA nephropathy is the most common glomerular disease, and a common cause of
chronic renal failure. In many national registries it accounts for around 10% of all
dialysis and transplant patients. 20-30% of patients with IgA nephropathy develop
end stage renal disease (requiring dialysis or a kidney transplant) within 10-20 years
from the diagnosis.
Hypertension, proteinuria and reduced renal function at diagnosis are identified as
the clinical risk factors for a poor outcome. On renal biopsy, an interstitial infiltrate is
the most commonly reported marker of adverse outcome. Multiple genetic loci
associated with disease risk have been identified. The prevalence of risk alleles
varies geographically, highest in eastern Asia and northern Europe, fewer in other
parts of Europe and North America, and the least in Africa.
There is growing evidence that IgAN is an immune complex -mediated disease. To
date, three key molecules have been implicated in IC formation, correlating with
disease progression: galactose-deficient IgA1 (Gd-IgA1), IgG anti-Gd-IgA1 antibodies,
and soluble CD89 (a Fc receptor for IgA). A better understanding of the multi-step
process of pathogenesis of IgA nephropathy and the genetic and environmental
contributing factors will lead to development of biomarkers to identify patients with
progressive disease who would benefit from a future disease-specific therapy.
This course will be held in the contest of the "14th International Symposium on IgA
Nephropathy". The scientific programme of the symposium touches most of the
state-of-the-art work in the field and the interactions between the attendees will give
the opportunity to review and discuss the topics.
The aim of the course is to provide the participants with the recent progress in the
genetics, pathogenesis and therapy of IgA nephropathy. The topics covered are
outstanding and they could offer the possibility of new investigations in the field.
Scientific content of the educational event:
A high level scientific update will be given in the following area of IgA nephropathy
Lectures (30 minutes + 30 minute discussion):
1) Genetics and environmental factors in IgAN: A. Gharavi (USA)
2) From genetics to tonsillar flora in IgAN: I. Narita (Japan)
3) Intestinal dysbiosis in IgAN: L. Gesualdo (Italy)
4) Role of streptococcal proteins in IgAN: D. Karpman (Sweden)
5) Pathogenic role of gluten in IgAN: R. Monteiro (France)
6) Meet the experts session- Genetics and environment in IgAN
7) Corticosteroids : data from VALIGA study: V. Tesar, (Czech Republic)
8) ARA surrogate end-points for IgAN: D. Cattran (Canada)
9) STOP IgAN Trial: J. Floege (Germany)
10) The NEFIGAN Trial: B. Fellstrom (Sweden)
11) Meet the experts session- Conventional and innovative therapy for IgAN.
Click here to download the Travel Grant application
Click here to download the programme.